Re-Evaluating Risks and Benefits in Human Subjects Research
By Jonathan Kahn, Biopolitical Times guest contributor
| 05. 25. 2011
Modern bioethics is grounded in four basic principles: respect for persons (i.e. autonomy), beneficence, nonmalificence and justice. In a recent presentation at the 2011 ELSI Congress, "Exploring the ELSI Universe," Malia Fullerton, a professor in the Department of Bioethics & Humanities at the University of Washington School of Medicine, noted that "respect for persons" and "beneficence" have come to be the preeminent values in bioethical review of human subjects studies, particularly in the context of IRB review. Respect for persons typically manifests in a concern for informed consent, and beneficence in a concern for weighing the potential harms and benefits of research. Fullerton argued that a more balanced consideration of the other values, particularly justice and a concern for persons not just in terms of consent but in terms of dignity, needed to be incorporated into such review.
This got me to thinking about these concepts and their deployment in current biomedical research. Beneficence has often been cast in terms of balancing costs and benefits, as though it were simply a utilitarian calculus. However, in the context of...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...